{"success":true,"data":{"pressRelease":{"id":"168598","rtpr_id":"nGNXDnG3K-20261014","ticker":"MDLN","exchange":"NASDAQ","all_tickers":["MDLN"],"title":"$MDLN Investors: A Securities Fraud Investigation is Pending on behalf of Medline Investors that Lost Money after 13% Stock Drop – Contact BFA Law  ","author":"Globe Newswire","published_at":"2026-10-14T10:46:00.105Z","article_body":"NEW YORK, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Leading securities law\nfirm Bleichmar Fonti & Auld LLP\n(https://www.globenewswire.com/Tracker?data=zrAA-w7Kk27cVQLuqyB4IUOfVPDoV-0EndWAZpyR0auMAh_LGMqo1OQWzp1nU2FA-UNxJf0C1sM-1InPdDzx6tIpF5lbrW_1dTzx7Dhjbvk0dto9YM0LDlHVcGOAzy1etrRvUnEIvOcrXM2qvONiIVTLw8qm-dFaCklnguH3pJw=)\nannounces an investigation into Medline Inc. (NASDAQ:MDLN) for potential\nsecurities fraud after its significant stock drops.\n\nIf you invested in Medline securities, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/medline-class-action-lawsuit.\n\nKey Details of the Medline ($MDLN) Class Action Investigation:\n* Investigation Overview: Securities fraud relating to Medline’s statements\nabout its manufacturing and product quality.\n* Stock Declines:\n                        June 2, 2026 – 7% Stock Drop\n\n                        August 5, 2026 – 13% Stock\nDrop\n* Action: Contact BFA Law\n(https://www.bfalaw.com/cases/medline-class-action-lawsuit) to discuss your\nrights\nWhy is Medline Being Investigated for Securities Fraud?\n\nMedline is a healthcare manufacturing and supply-chain company that retails\nand distributes medical and surgical products.\n\nBFA is investigating whether Medline misled investors about its manufacturing\nand product quality.\n\nWhy did Medline’s Stock Drop? \n\nOn June 2, 2026, the FDA published a warning letter detailing Medline’s\n“significant violations of Current Good Manufacturing Practice regulations\nfor finished pharmaceuticals” and stating that Medline “failed to\nthoroughly investigate any unexplained discrepancy or failure of a batch or\nany of its components to meet any of its specifications.”\n\nFollowing that announcement, Medline shares fell approximately 7% on June 2,\n2026.\n\nThen, before market hours on August 5, 2026, Medline acknowledged that at\nleast some of remediation steps taken to address the issues in the FDA’s\nwarning letter had “result[ed] in earnings loss” during the company’s\n2Q26 earnings call.\n\nFollowing that announcement, Medline shares fell approximately 13% on August\n5, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/medline-class-action-lawsuit.\n\nWhat Can You Do?\n\nIf you invested in Medline securities, you may have legal options and are\nencouraged to submit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/medline-class-action-lawsuit\n\nOr contact:\n\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named “Elite Trial Lawyers” by the National Law Journal,\n“Litigation Stars” by Benchmark Litigation, among the top “500 Leading\nPlaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’\nBar” by Law360 and “SuperLawyers” by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff’s securities litigation law firm, with clients\nnoting: “[t]here is no better service provider in the practice area,”\n“[t]he interest of the client is always front and center,” and “[t]here\nisn’t a better firm in this space.” One testimonial described the firm as\n“nimble and entrepreneurial,” with a “relentless focus on adding value\nfor clients.”\n\nAmong its recent notable successes, BFA recovered over $900 million in value\nfrom Tesla, Inc.’s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/medline-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/44a256cf-d470-4d8a-af6b-dbb1b5bbb11e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXDnG3K-20261014","title":"$MDLN Investors: A Securities Fraud Investigation is Pending on behalf of Medline Investors that Lost Money after 13% Stock Drop – Contact BFA Law  ","author":"Globe Newswire","ticker":"MDLN","created":"2026-10-14T10:46:00.105Z","tickers":["MDLN"],"exchange":"NASDAQ","article_body":"NEW YORK, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Leading securities law\nfirm Bleichmar Fonti & Auld LLP\n(https://www.globenewswire.com/Tracker?data=zrAA-w7Kk27cVQLuqyB4IUOfVPDoV-0EndWAZpyR0auMAh_LGMqo1OQWzp1nU2FA-UNxJf0C1sM-1InPdDzx6tIpF5lbrW_1dTzx7Dhjbvk0dto9YM0LDlHVcGOAzy1etrRvUnEIvOcrXM2qvONiIVTLw8qm-dFaCklnguH3pJw=)\nannounces an investigation into Medline Inc. (NASDAQ:MDLN) for potential\nsecurities fraud after its significant stock drops.\n\nIf you invested in Medline securities, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/medline-class-action-lawsuit.\n\nKey Details of the Medline ($MDLN) Class Action Investigation:\n* Investigation Overview: Securities fraud relating to Medline’s statements\nabout its manufacturing and product quality.\n* Stock Declines:\n                        June 2, 2026 – 7% Stock Drop\n\n                        August 5, 2026 – 13% Stock\nDrop\n* Action: Contact BFA Law\n(https://www.bfalaw.com/cases/medline-class-action-lawsuit) to discuss your\nrights\nWhy is Medline Being Investigated for Securities Fraud?\n\nMedline is a healthcare manufacturing and supply-chain company that retails\nand distributes medical and surgical products.\n\nBFA is investigating whether Medline misled investors about its manufacturing\nand product quality.\n\nWhy did Medline’s Stock Drop? \n\nOn June 2, 2026, the FDA published a warning letter detailing Medline’s\n“significant violations of Current Good Manufacturing Practice regulations\nfor finished pharmaceuticals” and stating that Medline “failed to\nthoroughly investigate any unexplained discrepancy or failure of a batch or\nany of its components to meet any of its specifications.”\n\nFollowing that announcement, Medline shares fell approximately 7% on June 2,\n2026.\n\nThen, before market hours on August 5, 2026, Medline acknowledged that at\nleast some of remediation steps taken to address the issues in the FDA’s\nwarning letter had “result[ed] in earnings loss” during the company’s\n2Q26 earnings call.\n\nFollowing that announcement, Medline shares fell approximately 13% on August\n5, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/medline-class-action-lawsuit.\n\nWhat Can You Do?\n\nIf you invested in Medline securities, you may have legal options and are\nencouraged to submit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/medline-class-action-lawsuit\n\nOr contact:\n\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named “Elite Trial Lawyers” by the National Law Journal,\n“Litigation Stars” by Benchmark Litigation, among the top “500 Leading\nPlaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’\nBar” by Law360 and “SuperLawyers” by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff’s securities litigation law firm, with clients\nnoting: “[t]here is no better service provider in the practice area,”\n“[t]he interest of the client is always front and center,” and “[t]here\nisn’t a better firm in this space.” One testimonial described the firm as\n“nimble and entrepreneurial,” with a “relentless focus on adding value\nfor clients.”\n\nAmong its recent notable successes, BFA recovered over $900 million in value\nfrom Tesla, Inc.’s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/medline-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/44a256cf-d470-4d8a-af6b-dbb1b5bbb11e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-14T10:46:00.178578615Z","server_sent_at_ms":1791974760178},"received_at":"2026-10-14T10:46:00.228Z","source_url":null},"analysis":{"id":"156865","press_release_id":"168598","analysis_json":{"industry":{"label":"Health Care Providers & Services","sector":"Health Care"},"redFlags":["FDA warning letter cited for significant CGMP violations in finished pharmaceuticals","Remediation costs caused earnings losses disclosed on 2Q26 call (13% one-day drop)"],"eventType":"legal_litigation","narrative":"Blechmar Fonti & Auld LLP announced an investigation into Medline for potential securities fraud tied to statements about manufacturing and product quality.\n\nThe release references an FDA warning letter on June 2, 2026 over CGMP violations (7% drop) and an August 5, 2026 earnings call where remediation steps caused earnings losses (13% drop).\n\nThis is law-firm solicitation, not an issuer disclosure; no class action has been certified and no settlement announced.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation — suppress; underlying FDA/remediation issues may warrant separate monitoring."},"keyFigures":{"customDimensions":{"stock_drop_june_2":"7%","stock_drop_august_5":"13%"}},"namedEntities":{"people":[{"name":"Adam McCall","role":"BFA Law contact attorney"}],"products":[],"companies":[{"name":"Medline Inc.","ticker":"MDLN","relationship":"investigation target"},{"name":"Blechmar Fonti & Auld LLP","relationship":"plaintiff law firm"},{"name":"Tesla, Inc.","relationship":"prior BFA recovery reference"},{"name":"Teva Pharmaceutical Ind. Ltd.","relationship":"prior BFA recovery reference"}],"dollarAmounts":[{"amount":"$900 million","context":"prior BFA recovery from Tesla board"},{"amount":"$420 million","context":"prior BFA recovery from Teva"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm (Bleichmar Fonti & Auld) solicitation announcing an investigation, not issuer disclosure. No filed-and-certified class action or settlement; boilerplate contact-the-firm marketing."},"tickerRelevance":{"others":[],"primary":"MDLN"},"globalImportance":15,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"recent-IPO-large-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingRiskNote":"FDA CGMP warning letter and remediation-driven earnings loss are real fundamentals risks"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Blechmar Fonti & Auld LLP announced an investigation into Medline for potential securities fraud tied to statements about manufacturing and product quality.\n\nThe release references an FDA warning letter on June 2, 2026 over CGMP violations (7% drop) and an August 5, 2026 earnings call where remediation steps caused earnings losses (13% drop).\n\nThis is law-firm solicitation, not an issuer disclosure; no class action has been certified and no settlement announced.","key_figures":{"customDimensions":{"stock_drop_june_2":"7%","stock_drop_august_5":"13%"}},"named_entities":{"people":[{"name":"Adam McCall","role":"BFA Law contact attorney"}],"products":[],"companies":[{"name":"Medline Inc.","ticker":"MDLN","relationship":"investigation target"},{"name":"Blechmar Fonti & Auld LLP","relationship":"plaintiff law firm"},{"name":"Tesla, Inc.","relationship":"prior BFA recovery reference"},{"name":"Teva Pharmaceutical Ind. Ltd.","relationship":"prior BFA recovery reference"}],"dollarAmounts":[{"amount":"$900 million","context":"prior BFA recovery from Tesla board"},{"amount":"$420 million","context":"prior BFA recovery from Teva"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-14T10:46:05.964Z","global_importance":15,"audience_relevance":12,"importance_components":{"tickerTier":"recent-IPO-large-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingRiskNote":"FDA CGMP warning letter and remediation-driven earnings loss are real fundamentals risks"}},"durationMs":5724,"modelName":"glm-5.3-flashx"}}